Omeros Corporation (OMER): Price and Financial Metrics

Omeros Corporation (OMER)

Today's Latest Price: $10.54 USD

0.32 (3.13%)

Updated Oct 27 6:55pm

Add OMER to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

OMER Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OMER is -0.62 -- better than only 5.58% of US stocks.
  • OMER's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.74% of US stocks.
  • As for revenue growth, note that OMER's revenue has grown 33.51% over the past 12 months; that beats the revenue growth of 86.1% of US companies in our set.
  • Stocks that are quantitatively similar to OMER, based on their financial statements, market capitalization, and price volatility, are DNN, CLSN, AVEO, PTCT, and BLCM.
  • Visit OMER's SEC page to see the company's official filings. To visit the company's web site, go to

OMER Stock Price Chart Interactive Chart >

Price chart for OMER

OMER Price/Volume Stats

Current price $10.54 52-week high $25.46
Prev. close $10.22 52-week low $8.50
Day low $10.02 Volume 560,000
Day high $10.65 Avg. volume 916,019
50-day MA $11.25 Dividend yield N/A
200-day MA $13.45 Market Cap 574.62M

Omeros Corporation (OMER) Company Bio

Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded in 1994 and is based in Seattle, Washington.

OMER Latest News Stream

Event/Time News Detail
Loading, please wait...

OMER Latest Social Stream

Loading social stream, please wait...

View Full OMER Social Stream

Latest OMER News From Around the Web

Below are the latest news stories about Omeros Corp that investors may wish to consider to help them evaluate OMER as an investment opportunity.

Omeros to Present at the Cantor Virtual Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The presentation is scheduled for Tuesday, September 15, 2020 at 11:20 a.m. EDT. The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company’s website at under “Events.” About Omeros Corporati

Business Wire | September 11, 2020

Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. FDA’s clearance of the IND allows the initiation of the clinical program for OMS906. A Phase

Business Wire | August 31, 2020

Omeros' COVID-19 Opportunity And Challenges

When I last wrote on Omeros (OMER) earlier this month, I did not expect to be revisiting so soon; however, its press release issued with its Q2 2020 earnings has scrambled the situation in a good way. This article reports on the several significant changes since my earlier article and...

Out of Ignorance on Seeking Alpha | August 17, 2020

The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical r...

Benzinga | August 11, 2020

Omeros rallies on positive narsoplimab data in severely ill COVID-19 patients

Omeros (OMER) jumps 45% premarket on increased volume in reaction to positive results from a compassionate-use study evaluating narsoplimab in severely ill COVID-19 patients with acute respiratory distress syndrome ((ARDS)) requiring mechanical ventilation.All receiving narsoplimab, a human monoclonal antibody that binds to an enzyme called mann-binding lectin-associated serine protease-2 (MASP-2), recovered...

Seeking Alpha | August 10, 2020

Read More 'OMER' Stories Here

OMER Price Returns

1-mo 5.93%
3-mo -22.78%
6-mo -34.66%
1-year -38.54%
3-year -31.82%
5-year -15.88%
YTD -25.20%
2019 26.48%
2018 -42.67%
2017 95.87%
2016 -36.94%
2015 -36.52%

Continue Researching OMER

Want to see what other sources are saying about Omeros Corp's financials and stock price? Try the links below:

Omeros Corp (OMER) Stock Price | Nasdaq
Omeros Corp (OMER) Stock Quote, History and News - Yahoo Finance
Omeros Corp (OMER) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8582 seconds.